Zevra Therapeutics (ZVRA) Cash from Operations (2014 - 2026)

Zevra Therapeutics has reported Cash from Operations for 13 years, with the latest figure at 6142000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 174.7% year-over-year to 6142000.0; the trailing twelve-month figure through Mar 2026 stood at 12766000.0 (up 120.68% YoY), and the FY2025 full-year result was 1598000.0, up 97.71% from the prior year.
• Cash from Operations for Q1 2026 stood at 6142000.0, up from 5516000.0 in the prior quarter.
• The five-year high for Cash from Operations was 6142000.0 in Q1 2026, with the low at 19109000.0 in Q2 2024.
• Historically, Cash from Operations has averaged 6904294.12 across 5 years, with a median of 4628000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 426.18% — and 2026, when it soared 174.7%.
• Zevra Therapeutics' Cash from Operations stood at 4462000.0 in 2022, then tumbled by 262.12% to 16158000.0 in 2023, then dropped by 0.57% to 16250000.0 in 2024, then soared by 133.94% to 5516000.0 in 2025, then climbed by 11.35% to 6142000.0 in 2026.
• The last three Cash from Operations figures came in at 6142000.0 (Q1 2026), 5516000.0 (Q4 2025), and 4709000.0 (Q3 2025), per Business Quant data.